1 For GT’s first anniversary we look back on our last 12 issues to see who in the industry earned the most mentions. Sure, it may say more about our coverage than anything else, but nevertheless, here are the GT darlings by number of issues mentioned:
10 Craig Venter
7 Francis Collins
Lee Hood
5 Ewan Birney
Eric Lander
Steve Lincoln
George Rathmann
4 Dan Joy
Jim Kent
Chris Marcazzo
2 In a fast-paced industry such as ours, fashions come and go. Here are the ins and outs of trends since GT’s inaugural issue:
Out In
Selling tools Drug discovery
IPOs Private funding
Startups Consolidation
SNPs Haplotypes
100,000 genes 30,000 genes
PE Applera
Genomics Proteomics
3 IPOs that did IPOs that didn’t
Brucker Daltonics Amersham Pharmacia
Ciphergen Biotech
Compugen Athersys
Genomica DoubleTwist
InforMax Genometrix
Third Wave NetGenics
4 Going, going…gone. These companies were swallowed up or shut their doors in the last 12 months:
Arcaris (acquired by Deltagen)
Artemis Pharmaceuticals (acquired by Exelixis)
Aurora Biosciences (acquired Vertex)
Axys Pharmaceuticals (acquired by Celera)
Cellmark Diagnostics (acquired by Orchid BioSciences)
Coelacanth (acquired by Lexicon Genetics)
Empatheon (acquired by eBioinformatics, now Entigen)
Gemini Genomics (acquired by Sequenom)
Genometrix (shut down)
GenomicFX (shut down)
Momentum Healthcare (acquired by Cellomics)
Neomorphic (acquired by Affymetrix)
Oxford Molecular (disbanded and software division acquired by Pharmacopeia)
Packard BioScience (acquired by PerkinElmer)
PanVera (acquired by Aurora Biosciences)
Principia Pharmaceutical (acquired by Human Genome Sciences)
Prospect Genomics (acquired by Structural GenomiX)
Proteome (aquired by Incyte)
Rosetta Inpharmatics (acquired by Merck)
Sawady (acquired by Qiagen)
Structure Function Genomics (acquired by GeneFormatics)
Synthetic Genetics (acquired by Epoch Biosciences)
Trega Biosciences (acquired by Lion Bioscience)
Xenometrix (acquired by Discovery PartnerInternational)